Network pharmacology analysis showed that some popular metabolic targets for the FDA-approved antidiabetic drugs, such as PPARG and PPARA, the targets of pioglitazone, might play a great role in MA activity against insulin resistance and dyslipidemia associated with T2DM. This evidence concerns the gene PPARA and metabolic syndrome.